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patients with chronic hepatitis C before alpha interferon (IFN) 
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initiate autoimmune thyroid disease by mimicking the 
structure of some component of thyroid tissue, by 
altering thyroid antigens in some way to make them 
more immunogenic or by activating T cells indepen- 
dently of antigen (5). The association between ATA and 
HCV seems to be not fortuitous. 
Reply: 
We read with interest the letter to the editor by Huang 
et al., who found only a 6.3% rate of increased anti- 
thyroid microsomal autoantibody levels in a retro- 
spective series of 79 patients with chronic hepatitis C. 
However, patients with chronic HCV infection tended to 
have a higher prevalence of abnormal thyroid function 
tests than did “healthy” controls and patients with 
chronic HBV infection. The prevalence of autoimmune 
thyroid disorders in patients with chronic hepatitis C 
seems to be lower in Taiwan than in France (1; Pateron 
et al., J Hepatol1993;17:417-419). Geographical hetero- 
geneity, genetic influence or both in autoimmune 
disease among different populations have been demon- 
strated (2) and might explain these different findings. 
In a recent study (31, we found more increased 
anti-Gor levels in anti-HCV-positive patients with ATA 
than in anti-HCV-positive patients without ATA. Gor 
antibodies distinct from anti-HCV are supposed to have 
dual specificities; they target both the presumed core 
gene product of HCV and a host nuclear component. 
This cross-recognition is probably derived from ho- 
mologous regions between the Gor epitope and a viral 
epitope on the core protein in HCV. We therefore suggest 
that anti-Gor is an autoantibody induced by HCV 
infection (4). Thus an infectious agent (e.g., HCV) could 
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Assessment of Central Blood Volume in Cirrhosis by Radionuclide Angiography: 
What Does It Really Mean? 
To the Editor: 
The pathogenesis of fluid retention and formation of 
ascites in cirrhosis is still unclear, but the size of the 
central vascular compartment - where volume receptors 
and baroreceptors are located - is apparently important. 
We recently provided evidence that central and arterial 
blood volume is reduced in such patients (1, 2). Wong 
et al. (31, however, reported in a recent issue of 
HEPATOLOGY that the central blood volume is increased 
as assessed on radionuclide angiography . We have 
serious reservations about their conclusion. First, we 
are concerned about the reliability and accuracy of their 
radionuclide method. Second, we find their observation 
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incompatible with several other physiological changes 
observed in these patients. 
Wong et al. (3) determined end-diastolic and end- 
systolic left ventricular volumes, stroke volume and 
cardiac output by means of an ECG-gated gamma- 
camera technique after blood pool labeling with 
99mTc-pertechnetate/stannous pyrophosphate. Ref- 
erence counts of venous blood were performed for 
calculation of the ventricular volume according to  the 
method of Links et al. (4). This is a well-established 
radionuclide technique, and we do agree on the reported 
accuracy of the left ventricular ejection fraction and the 
ventricular volume (5). With this method, Wong et al. (3) 
found the left ventricular volume to be normal in 
cirrhosis, a finding we can support from the results of a 
study in which magnetic resonance imaging was used 
(Maller S, et al., Unpublished observations). We found 
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stroke volumes of 88 ? 5 ml and 81 +- 8 ml in controls 
and cirrhotic patients, respectively, values very similar 
to those recorded by Wong et al. 
We are seriously concerned that Wong et al. extended 
the standard technique for determining ventricular 
volume to include blood volumes of the thorax (central 
blood volume [i.e., blood volume in lungs, heart, and 
central vascular bed]). They used a single anterior 
large-field-of-view gamma-camera image of the thorax 
and calculated the ratio of the pulmonary and central 
vascular blood volume to the ventricular volume on the 
basis of specific counts in each structure. The blood 
volumes of the thorax were then back-calculated from 
the ventricular volume determined by means of the 
ECG-gated standard technique. In fact, this procedure 
requires an up to 20-fold extrapolation maneuver to get 
from the blood volume of the left ventricle (end-systolic 
volume, 63 ml; end-diastolic volume, 161 ml) to the 
central blood volume (3,462 ml), a procedure that is very 
sensitive to even minor inaccuracies and heterogeneity 
of attenuation. According to the authors, “The pul- 
monary blood volume calculation required no further 
attenuation correction because the cardiac ventricles 
and pulmonary vasculature occupy the same image 
plane in the thorax.” This is not correct. When the same 
attenuation correction is used for the thorax as a whole 
as for the left ventricle, major errors may arise ( 6 ) .  In 
this context, it should be recalled that the distance for 
50% attentuation of 99mTc-labeled photons in tissue is 
only about 6 cm (4). Moreover, the references Wong et al. 
quote for pulmonary blood estimation (6-8) specifically 
stress that the radionuclide technique only provides an 
index of the change in pulmonary blood volume in the 
single subject or animal, not an absolute value. 
Separation of thoracic from abdominal radioactivity 
may also be problematic. In patients with ascites, the 
liver and spleen are often dislocated toward the thorax. 
Because the radionuclide accumulates in blood in these 
organs, this may easily lead to overestimation of the 
central blood volume as determined with that radionu- 
clide method. Wong et al. reported an average central 
blood volume of 3,295 ml in their patients with ascites. 
Although there is general agreement that patients with 
ascites exhibit an expanded total blood volume (9), a 
central blood volume of 3.3 L is rather unlikely: Because 
splanchnic and other noncentral vascular areas are 
known to be expanded in these patients, the total blood 
volume would amount to extremely high and somewhat 
unlikely values. Unfortunately, Wong et al. did not 
report values for total blood volume in their patients. 
Thus the radionuclide method used by Wong et al. is 
not suitable for measurement of the central blood 
volume; it is very uncertain and upwardly biased. 
Accordingly, Dock et al. (10) and de Freitas et al. (11) 
found the normal pulmonary blood volume to be 246 to 
310 ml/m2 in contrast to the 412 ml/m2 reported by 
Wong et al. Reliable and accurate values of central and 
pulmonary blood volumes rendered by radionuclide 
angiography require the combination of bolus and 
equilibrium techniques (12, 13). 
Several findings in this study (3) argue against the 
authors’ conclusion. Their patients with ascites had 
decreased systemic vascular resistance and increased 
heart rate and cardiac output, and they showed a trend 
toward increased plasma norepinephrine, renin activity 
and aldosterone levels. These findings are typical for a 
hyperdynamic circulation with central underfilling, as 
observed in many other reports in decompensated 
cirrhosis (1, 9, 14, 15). Furthermore, the authors have 
previously reported suppression of greatly increased 
plasma catecholamines and augmented natriuresis after 
implantation of a peritoneovenous shunt in ascitic 
patients (16). Because this procedure leads to central 
volume expansion, these findings indicate that salt and 
water retention are at least in part due to central 
vascular underfilling. It seems quite difficult to rec- 
oncile these results with Wong’s present finding of 
expanded central blood volume in cirrhosis. Moreover, 
the total lack of correlation between neurohumoral 
indicators of central blood volume and the reported 
values of central blood volume (3) again argues against 
the conclusion. 
In our opinion, the report by Wong et al. (3) 
does not offer sufficient evidence against the conten- 
tion of central vascular underfilling in decompensated 
cirrhosis. 
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Reply: 
We have read the thoughtful letter by Henriksen and 
colleagues and would like to offer the following clarifi- 
cation. 
We agree with Dr. Henriksen that none of the 
techniques for the indirect determination of central 
blood volume is perfect. Each technique has its strength 
and weaknesses; the ultimate balance lies in the specific 
situation for which the method is applied. We have 
chosen to use the equilibrium count-based technique to 
calculate volume to circumvent significant noncor- 
rectable errors of the first-pass technique (1). This is in 
keeping with the generally accepted principle in nuclear 
medicine: First-pass techniques are useful in measuring 
flow, and equilibrium techniques are useful in mea- 
suring volume (2). 
Dr. Henriksen has employed the first-pass tracer- 
clearance technique by injecting radioiodinated albumin 
in the right atrium and collecting blood samples a t  1-sec 
intervals in the aorta (3). The volume is calculated as 
V = F x T ,  where V is apparent volume of distribution 
of tracer, F is rate of blood flow and T is mean transit 
time of the tracer. This equation is based on sound 
theoretical physiological principles predicated on ideal 
circumstances that often do not exist in the real patient. 
The major weakness of this technique lies in the fact that 
for nondiffusible tracers such as albumin there is a 
significant nonlinearity of the equation when flow 
increases (2). The volume calculated by this technique 
represents the blood volume occupied by the tracer. 
HWWILUI.I 1994;20:1654-1655. 
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However, as flow or cardiac output increases, such as in 
the case in cirrhosis, there will be inadequate time for 
homogeneous mixing of the tracer with the total central 
blood volume, leading to underestimation of the true 
central volume. This violates one of the major assump- 
tions that the authors themselves asserted (i.e., the 
requirement of complete indicator mixing [31). One may 
therefore reliably predict that whenever cardiac output 
increases, the first-pass technique will underestimate 
the true volume. 
Further concerns with the techniques described above 
include the problem of central shunts. The authors have 
realized this weakness and took an entire appendix to 
address this point. However, throughout the discussion 
the author assumed that a linear relationship would 
exist between flow, transit time and volume. This 
relationship again, unfortunately, does not stay linear 
when the flow is increased, as in the setting of central 
shunts. Another potential problem that was not ad- 
dressed by the authors was the potential trapping or 
adherence of the labeled albumin to the pulmonary 
vascular endothelium, or extravasation of the tracer 
outside the intravascular space. Loss of tracer during a 
first-pass study will immediately lead to underesti- 
mation of the blood volume. This point was not ad- 
dressed by the authors. The authors could have used 
labeled RBCs instead, and at  the same time may have 
had the opportunity to try out our equilibrium tech- 
nique. 
To address these concerns, we have performed central 
blood volume calculation with the well-accepted 
counted-based technique. Please note that most of the 
recent important studies on central blood volume 
changes use the equilibrium blood pool method (4 ,5) .  We 
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are delighted to find that Dr. Henriksen and colleagues 
agree with the general principles underlying this tech- 
nique and with the accuracy of the left ventricular 
volume determinations. They were concerned that po- 
tential errors in left ventricular volume calculation 
might lead to huge errors in central blood volume 
calculation, which may be 20 times larger in quantity. 
However, in our laboratory and as originally described 
(61, the error is usually maximally in the range of 5 ml. 
Therefore, even if the error is maximal, we would have 
at most 100 ml of overestimation. This still does not 
explain the difference of 600 ml/m2 in central blood 
volume between cirrhotic and normal subjects. 
The authors were also concerned about attenuation 
differences between the central vascular structures and 
the heart. The authors are accurate in that the count- 
based equilibrium techniques must take into account 
the tracer attentuation factor. Tracer attenuation is 
proportional to the distance between the structure being 
imaged and the gamma camera, and the composition of 
the attenuating tissue-in this case, mainly the chest 
wall. We have taken careful attenuation correction for 
the left ventricle using the standard triagulation method 
that Dr. Henriksen has already accepted as accurate (6). 
We would assert that the chest wall over the heart is 
similar to that over the lung and great vessels; it is 
mostly composed of tissue containing significant amount 
of water. We did make an assumption that the great bulk 
of central blood volume in the chest is a similar distance 
from the camera as the heart, when the patient is in a 
supine position. We may argue that we may in fact 
underestimate the central blood volume as a result of the 
possibly more posterior location of the main pulmonary 
blood volume when the patient is supine. 
The authors quoted Bell’s study (71, stating that if the 
same attenuation was used for the lung as the heart, 
major errors might arise. However, Bell was studying a 
dog model, which has a completely different chest wall 
morphology, and markedly different heart and lung 
position from an overlying camera. Here we are studying 
patients. The quote that “Radionuclide technique can 
only provide an index in the change of pulmonary blood 
volume, and not absolute value” was taken out of 
context; the purpose of the particular study quoted was 
to specifically examine pulmonary blood volume ratio 
between the lung and heart during exercise, as an 
indication of exercise-induced heart failure in patients 
with ischemic heart disease (8). 
The authors were also concerned about difficulties in 
separating abdominal from chest organs in the supine 
position in the cirrhotic patients. We use the diaphragm 
as the dividing line between the chest and abdomen. This 
is usually very distinct on the radionuclide image. 
Unless the authors suggest that abdominal organs can 
herniate through the diaphragm into the chest, contrib- 
uting to extra radioactivity, this assertion is hightly 
improbable. The authors were also concerned about the 
unusually high central blood volume measured. Please 
keep in mind, however, that this value does include all 
vascular structutes in the chest cavity, including the 
inferior vena cava above the diaphragm, all central 
vascular structures and all central shunts. 
The authors were similarly concerned that our es- 
timate of pulmonary blood volume of 412 ml/m2 in 
normal subjects was too high. It is interesting that the 
authors have given examples in their paper of normal 
pulmonary blood volume as 650 ml, which for a normal 
person with body surface area of 1.7 m2 yields a value of 
382 ml/m2 supporting our measurement. 
Despite the emphasis that the measurement of central 
blood volume includes all the vascular structures in the 
thoracic cavity, Hendriksen et al. consider that a central 
blood volume of 3.3 L “is rather unlikely.’’ It is true that 
we did not measure total blood volume in our patients 
but this has been reported in several publications. For 
example, Boyer et al. (9) reported blood volumes in 
patients with portal hypertension ranging from 78.5 to 
123 mlkg, or 5.7 to 9.6 L. Therefore a CBV of 3.3 L in 
such circumstances does not seem unreasonable. 
We agree with the authors that, in patients with 
decompensated cirrhosis and ascites, the findings of 
hyperdynamic circulation and increased levels of sodium 
retaining factors speak in favor of central underfilling. 
However, where we disagree here is that in our view this 
is due to massive vasodilatation (lo),  leading to a greater 
increase in vascular capacity and a n  inadequate increase 
in intravascular blood volume, despite the intense 
sodium retention resulting from the vasodilatation (10). 
In contrast, in well-compensated cirrhotic patients, all 
previous publications have emphasized the tendency for 
an increased total blood volume in the absence of any 
manifestations of “underfilling” (9, 11-14). Therefore 
an increased central blood volume, as opposed to a 
decreased central blood volume as reported by the 
authors (3), would be in keeping with this, together with 
increases of plasma trial natriuretic levels (151, and 
suppression of plasma renin activity and serum aldo- 
sterone levels (16-181, in such patients. 
Overall, we have found Dr. Henriksen’s arguments 
interesting and thoughtful. We appreciate the oppor- 
tunity to clarify these points of contention and thank 
them for the healthy degree of controversy and intel- 
lectual challenge. 
FLORENCE WONG, M.D., FRACP 
PETER LIU, M.D., FRCP(C) 
LAURENCE BLENDIS. M.D., 
FRCP(C) 
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Complications of Transplantation 
To the Editor: 
In a recent issue of this JOURNAL, Rank et al. (1) 
reported their experience with eight patients with 
end-stage protoporphyric liver disease in whom they 
found evidence of neurological dysfunction. 
We would like to add the report of a 58-yr-old woman 
in whom liver transplantation for fulminant liver failure 
in erythropoietic protoporphyria was complicated by 
severe polyneuropathy . 
In this patient, erythropoietic protoporphyria with 
asymptomatic liver involvement had been diagnosed 12 
yr earlier. For years she had suffered from paresthesias, 
dysesthesias and nocturnal myoclonias of the legs. 
Somatosensory evoked potentials of the tibia1 nerve 
were slightly lengthened; diagnosis of a discrete poly- 
neuropathy had been made. 
In December 1992, the patient was seen with unchar- 
acteristic abdominal pain and mild jaundice. Liver 
function rapidly declined, and hepatic encephalopathy 
(grade 3) developed. Orthotopic liver transplantation 
was successfully performed 5 wk after the initial 
presentation. The day after transplantation, respiratory 
insufficiency with loss of consciousness suddenly de- 
veloped. The patient had to be reintubated and was 
artificially ventilated for 5 wk. A neurological exami- 
nation immediately after reintubation revealed no ab- 
normality. A cranial computed tomography scan did not 
show any pathological findings except for moderate 
brain atrophy. 
Some days after the operation, however, the patient 
showed no spontaneous movement except for minimal 
movements of lower arms and hands. Gag and cough 
reflexes were absent. The electromyogram confirmed the 
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for Protoporphyric Liver Disease 
diagnosis of severe polyneuropathy with axonal degen- 
eration and marked signs of muscle denervation. Six 
weeks after transplantation, there was still the clinical 
picture of an acute polyneuropathy with involvement of 
cranial nerves VI, VII and XII. 
Considering a causal relationship between the immu- 
nosuppressant FK 506 and polyneuropathy, we changed 
immunosuppression to cyclosporine. Two weeks later, 
the patient had repeated cerebral seizures. EEG showed 
a diffuse cerebral functional disorder without focal 
changes. 
With intensive physiotherapy, neurological deficits 
gradually improved. One year after transplantation, 
strength in the patient’s legs is still markedly reduced. 
The patient is not able to walk more than 20 m, and she 
shows a markedly atactic gait due to polyneuropathy. 
Tendon reflexes of the lower limbs are still absent, and 
there is a considerable degree of dysesthesia and pall- 
hypesthesia of the legs. The patient complains of 
disorders of balance, orthostatic dysregulation and 
profuse sweating. 
This case shows striking similarities to patient 4 
described by Rank et al. (1) and to another case 
published recently by Herbert et al. (2). In all three of 
these patients, severe polyneuropathy with axonal de- 
generation and cranial nerve involvement developed 
immediately after liver transplantation for erythro- 
poietic protoporphyria. Furthermore, our patient and 
the patient reported by Herbert et al. complained of 
symptoms indicating mild polyneuropathy some years 
before deterioration of liver function. 
Considering the small number of liver transplanta- 
tions for EPP reported until now, there is substantial 
evidence for the induction or aggravation of severe 
neurological dysfunction after the operation. Especially 
in patients with histories of mild peripheral polyneuro- 
pathy, the physician must be aware of sudden and 
